Improved procedural workflow for catheter ablation of paroxysmal AF with high-density mapping system and advanced technology: Rationale and study design of a multicenter international study.
LumipointTM
antral potential
atrial fibrillation
catheter ablation
high-density mapping system
local impedance
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
11
02
2022
received:
23
12
2021
accepted:
17
02
2022
pubmed:
22
4
2022
medline:
10
6
2022
entrez:
21
4
2022
Statut:
ppublish
Résumé
The antral region of pulmonary veins (PV)s seems to play a key role in a strategy aimed at preventing atrial fibrillation (AF) recurrence. Particularly, low-voltage activity in tissue such as the PV antra and residual potential within the antral scar likely represent vulnerabilities in antral lesion sets, and ablation of these targets seems to improve freedom from AF. The aim of this study is to validate a structured application of an approach that includes the complete abolition of any antral potential achieving electrical quiescence in antral regions. The improveD procEdural workfLow for cathETEr ablation of paroxysmal AF with high density mapping system and advanced technology (DELETE AF) study is a prospective, single-arm, international post-market cohort study designed to demonstrate a low rate of clinical atrial arrhythmias recurrence with an improved procedural workflow for catheter ablation of paroxysmal AF, using the most advanced point-by-point RF ablation technology in a multicenter setting. About 300 consecutive patients with standard indications for AF ablation will be enrolled in this study. Post-ablation, all patients will be monitored with ambulatory event monitoring, starting within 30 days post-ablation to proactively detect and manage any recurrences within the 90-day blanking period, as well as Holter monitoring at 3, 6, 9, and 12 months post-ablation. Healthcare resource utilization, clinical data, complications, patients' medical complaints related to the ablation procedure and patient's reported outcome measures will be prospectively traced and evaluated. The DELETE AF trial will provide additional knowledge on long-term outcome following a structured ablation workflow, with high density mapping, advanced algorithms and local impedance technology, in an international multicentric fashion. DELETE AF is registered at ClinicalTrials.gov (NCT05005143).
Sections du résumé
BACKGROUND
BACKGROUND
The antral region of pulmonary veins (PV)s seems to play a key role in a strategy aimed at preventing atrial fibrillation (AF) recurrence. Particularly, low-voltage activity in tissue such as the PV antra and residual potential within the antral scar likely represent vulnerabilities in antral lesion sets, and ablation of these targets seems to improve freedom from AF. The aim of this study is to validate a structured application of an approach that includes the complete abolition of any antral potential achieving electrical quiescence in antral regions.
METHODS
METHODS
The improveD procEdural workfLow for cathETEr ablation of paroxysmal AF with high density mapping system and advanced technology (DELETE AF) study is a prospective, single-arm, international post-market cohort study designed to demonstrate a low rate of clinical atrial arrhythmias recurrence with an improved procedural workflow for catheter ablation of paroxysmal AF, using the most advanced point-by-point RF ablation technology in a multicenter setting. About 300 consecutive patients with standard indications for AF ablation will be enrolled in this study. Post-ablation, all patients will be monitored with ambulatory event monitoring, starting within 30 days post-ablation to proactively detect and manage any recurrences within the 90-day blanking period, as well as Holter monitoring at 3, 6, 9, and 12 months post-ablation. Healthcare resource utilization, clinical data, complications, patients' medical complaints related to the ablation procedure and patient's reported outcome measures will be prospectively traced and evaluated.
DISCUSSION
CONCLUSIONS
The DELETE AF trial will provide additional knowledge on long-term outcome following a structured ablation workflow, with high density mapping, advanced algorithms and local impedance technology, in an international multicentric fashion. DELETE AF is registered at ClinicalTrials.gov (NCT05005143).
Identifiants
pubmed: 35446440
doi: 10.1002/clc.23806
pmc: PMC9175242
doi:
Banques de données
ClinicalTrials.gov
['NCT05005143']
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
597-604Subventions
Organisme : Boston Scientific Corporation
Informations de copyright
© 2022 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Références
Circ Arrhythm Electrophysiol. 2020 Sep;13(9):e008446
pubmed: 32718185
Europace. 2017 May 01;19(5):784-794
pubmed: 28065886
Pacing Clin Electrophysiol. 2021 Dec;44(12):2031-2040
pubmed: 34606098
Europace. 2016 Apr;18(4):531-7
pubmed: 26346921
Circ Arrhythm Electrophysiol. 2016 Jan;9(1):e003337
pubmed: 26763226
Cardiovasc Diagn Ther. 2019 Oct;9(Suppl 2):S247-S263
pubmed: 31737533
Indian Pacing Electrophysiol J. 2015 Jul 29;15(3):152-7
pubmed: 26937108
J Cardiovasc Electrophysiol. 2017 Sep;28(9):1037-1047
pubmed: 28639728
Heart Rhythm. 2018 Aug;15(8):1158-1164
pubmed: 29729399
HeartRhythm Case Rep. 2019 Jun 07;5(10):494-496
pubmed: 31700792
Europace. 2021 Jul 18;23(7):1042-1051
pubmed: 33550380
J Cardiovasc Electrophysiol. 2021 Jun;32(6):1540-1548
pubmed: 33851484
Europace. 2018 Nov 1;20(FI_3):f351-f358
pubmed: 28637187
Circulation. 2015 Oct 6;132(14):1311-9
pubmed: 26283655
J Cardiovasc Electrophysiol. 2020 Sep;31(9):2319-2327
pubmed: 32613661
Europace. 2020 Nov 1;22(11):1645-1652
pubmed: 32879974
Clin Cardiol. 2022 Jun;45(6):597-604
pubmed: 35446440
Europace. 2019 Aug 1;21(Supplement_3):iii2-iii4
pubmed: 31400218
J Cardiovasc Electrophysiol. 2021 Jun;32(6):1549-1552
pubmed: 33851472
Am J Cardiol. 1994 Aug 1;74(3):242-6
pubmed: 8037128
BMJ Open. 2019 Jun 11;9(6):e023775
pubmed: 31189669
Europace. 2019 Aug 1;21(Supplement_3):iii7-iii10
pubmed: 31400216
Circulation. 1998 Sep 8;98(10):953-60
pubmed: 9737514
Heart Rhythm. 2015 Sep;12(9):1927-34
pubmed: 26001505
J Cardiovasc Electrophysiol. 2020 Jul;31(7):1694-1701
pubmed: 32369225
Pacing Clin Electrophysiol. 2003 Jul;26(7 Pt 2):1576-82
pubmed: 12914606
N Engl J Med. 2016 Jun 9;374(23):2235-45
pubmed: 27042964
Future Cardiol. 2020 Nov;16(6):735-751
pubmed: 32608246
HeartRhythm Case Rep. 2020 Nov 07;7(2):65-68
pubmed: 33665103
Pacing Clin Electrophysiol. 2019 Jul;42(7):1056-1062
pubmed: 31116439
Heart. 2012 Feb;98(4):297-302
pubmed: 22095616
JACC Clin Electrophysiol. 2016 Aug;2(4):474-483
pubmed: 29759868